Phase 3 HIV vaccine efficacy trial being launched in the Americas and Europe

  • National Institutes of Health
  • National Institutes of Health
  • 15 Jul 2019

  • curated by Priscilla Lynch
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

A phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America and Europe will open for enrolment later this year.

The HPX3002/HVTN 706 trial (Mosaico) will enrol 3,800 HIV-negative men and transgender people aged 18 to 60 years who have sex with men and/or transgender people. It will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition in this population.

All Mosaico participants will be offered a comprehensive HIV prevention package, including access to pre-exposure prophylaxis (PrEP) and will be randomly assigned to receive either the investigational vaccine regimen or a placebo. Vaccinations will be given at four time points over one year.

The experimental regimen comprises four doses of Ad26.Mos4.HIV, a vaccine candidate that uses an engineered common-cold virus (adenovirus serotype 26, or Ad26) to deliver four mosaic immunogens.

The final two vaccinations will be given together with a bivalent HIV envelope protein formulation, combining clade C gp140 and mosaic gp140 envelope proteins, adjuvanted by aluminium phosphate to boost immune responses.

A complementary phase 2b study in women called HPX2008/HVTN 705 (Imbokodo), launched in 2017 in five southern African countries, is ongoing.